Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease

Last updated: April 14, 2009
Sponsor: Lawson Health Research Institute
Overall Status: Completed

Phase

3

Condition

Kidney Failure

Focal Segmental Glomerulosclerosis

Renal Failure

Treatment

N/A

Clinical Study ID

NCT00506506
R-07-358
13514
  • Ages > 18
  • All Genders

Study Summary

N-acetylcysteine is used to reduce the risk of injury to the kidney after the administration of contrast dye. The mechanism and effectiveness of this intervention is not substantiated in the literature. The investigators hypothesize that serum creatinine will be lower in patients who receive NAC compared to those who receive the placebo but serum cystatin C will not change in patients who receive NAC compared to those who receive the placebo. Also urine creatinine will increase after the administration of NAC compared to before the administration of NAC.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine and patient weight.

  2. Age > 18

  3. No known allergies to or adverse effects from NAC

  4. No known scheduled radio-contrast procedures

  5. No medications known to affect creatinine secretion

Study Design

Total Participants: 60
Study Start date:
October 01, 2007
Estimated Completion Date:
October 31, 2008

Connect with a study center

  • London Health Sciences Centre

    London, Ontario N6A 5W9
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.